Immutep Efti Excellent Survival Data in Non-Small Cell Lung Cancer Trial

 

• Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations:
  • Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0%
• Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controls
• Safety continues to be favourable with no new safety signals
• INSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase III trial

https://www.globenewswire.com/news-release/2024/11/14/2981173/0/en/Immutep-s-Efti-Shows-Excellent-Survival-Data-from-INSIGHT-003-Trial-in-Non-Small-Cell-Lung-Cancer.html